健脾降脂颗粒配合肝病治疗仪治疗脂肪肝86例疗效观察

脂肪肝是临床常见病之一,而服用过度的降脂药物会加重肝脏的负担,采用中药健脾降脂颗粒配合HD-肝病治疗仪对脂肪肝治疗效果显著.经治的86例病人均为门诊经超声波检查诊断为脂肪肝,并感到明显乏力,不能胜任日常工作,肝区胀痛,腹泻,肝功能化验丙氨酸转移酶﹙ALT﹚轻度增高,多数病人属酒精、营养失衡所致的慢性脂肪肝,其中男性56例,女性30例,平均年龄37.6岁,对照组70例.治疗组在服健脾降脂颗粒的基础上加用肝病治疗仪,结果主要症状、体征及肝功能等改善均优于对照组﹙P〈0.05-0.01）.     

牛珀至宝微丸对内毒素休克肺组织核转录因子-κB表达的调控

目的观察牛珀至宝微丸对内毒素休克肺损伤时核转录因子-κB表达的影响。方法静脉注射内毒素(LPS)1.5mg/kg、腹腔注射D-氨基半乳糖(D-GalN)100mg/kg造成内毒素休克模型,用牛珀至宝微丸作预治疗处理,免疫组化方法检测NF-κB在肺组织内的表达。结果LPS组阳性表达部位在细胞核,牛珀至宝微丸组表达部位主要在细胞质。牛珀至宝微丸降低NF-κB表达,肺损伤减轻。结论证实牛珀至宝微丸能降低内毒素休克时肺组织NF-κB表达,改变其表达部位,提示牛珀至宝微丸对内毒素休克造成的肺损伤的保护作用可能是通过调控肺组织NF-κB而产生的。     

Drug Release Mechanism from a Microcrystalline Cellulose Pellet System

A common form of modified release is the encapsulation of specially formulated or coated pellets. An important first step in the development of a multiparticulate coated dosage form is to characterize the uncoated pellet. In earlier work, an uncoated pellet system developed in these laboratories and prepared from microcrystalline cellulose (MCC) was investigated and found to exhibit both the physical characteristics of an inert matrix and varying degrees of in vitro modified release. The use and characterization of MCC as a spheronization matrix material forms the basis for this formulation study. The drug release mechanism has been verified by varying selected formulation factors and evaluating the resulting pellets according to the relationship developed by T. Higuchi for granular inert matrices. In all cases, this MCC pellet system adhered to the theoretical relationships and the drug release mechanism can, therefore, be classified as an inert matrix.     

黄芪对COPD患者肺功能改善作用的研究

目的 :观察黄芪颗粒对慢性阻塞性肺疾病 (COPD)患者肺功能的改善作用。方法 :选择符合COPD诊断标准 ,1s用力呼气容积 (FEV1)占预计值百分比 <80 % ,1s用力呼气容积 /用力肺活量 (FEV1/FVC) <70 %的患者 80例 ,随机分为治疗组 (4 0例 )和对照组 (4 0例 ) ,分别予黄芪颗粒和长效茶碱治疗 3周 ,观察治疗前后肺功能情况及症状改善情况。结果 :治疗组肺功能改善明显 ,与治疗前比较P <0 .0 1,与对照组比较P <0 .0 5。结论 :黄芪颗粒能明显改善COPD患者肺功能及临床症状     

挤出滚圆造粒法制备氨咖黄敏胶囊的工艺研究

目的 研究微丸制备的最佳工艺和处方。方法 用新型挤出滚圆造粒机制备氨咖黄敏胶囊，以微丸的外观性状、堆密度、休止角和成丸率为参考因素优化工艺、筛选处方。结果 用优化的工艺和筛选的处方制得的微丸外观圆整、微丸大小分布均匀、成丸率高。结论 用挤出滚圆法制备氨咖黄敏胶囊，造粒容易，效率高，工艺简便，成本降低。     

Orbital foreign body masquerading as conjunctival melanoma 60 years after injury

A 74-year-old man presented with a 6-month history of a pigmented conjunctival lesion on his left eye. The lesion was initially suspicious for conjunctival melanoma. The patient admitted to a remote history of trauma from a airgun pellet over 60 years ago. Anterior examination revealed a 6 x 6 mm pigmented left conjunctival lesion and B-scan of the lesion was suggestive of a retained orbital foreign body. The lesion was removed through a transcaruncular medial orbitomy and pathology showed a retained orbital foreign body. A newly pigmented conjunctival lesion although initially concerning for melanoma represented a retained orbital body that surfaced many years after the initial orbital trauma.     

灯盏花素缓释微丸制备工艺与处方优化的研究

目的 考察灯盏花素缓释微丸的制备工艺和最优处方，并对释药机制进行探讨。方法 利用挤出滚圆法制备骨架型微丸，采用单因素考察和正交设计筛选最优处方，通过方程拟合探讨释药机制。结果 所得微丸的制备工艺简单，微丸大小均匀，载药量大且药物含量均匀，能达到缓释12h的试验设计要求；释药机制以药物扩散为主，兼有骨架溶蚀。结论 利用挤出滚圆法制备灯盏花素缓释微丸方法简单，适于工业化生产。     

Effects of anti-inflammatory drugs on urinary excretion of prostaglandin metabolites in cotton pellet inflammation

The influence of cotton pellet inflammation in rats and the effect of prednisolone and indomethacin on the excretion of the main urinary metabolite (MUM)s of prostaglandin (PG) F and E types were studied. After cotton pellet implantation, the excretion of PGE-MUM and F-MUM was progressively increased. In the early phase of inflammation, the excretion of PGE-MUM and PGF-MUM was suppressed by administration of indomethacin. However, prednisolone suppressed only PGF-MUM excretion in the early phase of inflammation. These results indicate that no direct interaction was obtained between the inhibition of the inflammatory response by prednisolone and indomethacin and PGs-MUM excretion in inflamed rats.     

步长稳心颗粒对原发性高血压患者心率变异性的影响

目的 探讨步长稳心颗粒对原发性高血压患者心率变异性的影响作用.方法 选择某院收入的原发性高血压患者86例,患者根据治疗方式不同分为两组,步长稳心颗粒组及对照组,对照组给予卡托普利治疗,步长稳心颗粒组在卡托普利治疗基础上添加步长稳心颗粒,对比两组治疗后血压变化及心率变异性相关指标变化.结果 步长稳心颗粒组及对照组患者治疗后收缩压与舒张压均显著较治疗前降低,结果对比差异有统计学意义(P＜0.05).步长稳心颗粒组治疗后SDNN、SDANN、rMSSD显著高于治疗前及对照组治疗后(P＜0.05).两组患者治疗前后LF、HF、L/H对比显示,步长稳心颗粒组治疗后HF、L/H与治疗前及对照组治疗后对比差异有统计学意义(P＜0.05).结论 原发性高血压患者应用步长稳心颗粒不但可显著降低血压,并能够显著改善患者心率变异性.